Clinical Trial Update: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating blinatumomab for younger patients with relapsed B-cell acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent B Acute Lymphoblastic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-12-06